Insmed hits more than two-decade high as rare lung disease drug succeeds in trial

Insmed

10/06/2025 19:18

Updates

** Shares of drugmaker Insmed INSM.O rise as much as 30% to a nearly 24-year high of $91.86

** Co says its treprostinil palmitil inhalation powder met the main goal in a mid-stage trial by reducing blood flow resistance in the lungs by 35% when compared to placebo

** Stock set for its best day in over a year, if gains hold

** The drug was tested in patients with Pulmonary Arterial Hypertension (PAH), a rare disease caused by a constriction of arteries in the lungs, leading to high blood pressure

** Insmed says it plans to start a separate late-stage trial for the drug in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD)

** PH-ILD is a condition where lung scarring leads to high blood pressure in the lung arteries

     ** Rivals United Therapeutics UTHR.O and Liquidia LQDA.O, both of which have approved drugs for PH-ILD, fell 15.5% and 22.7% respectively

** Co says the treatment is administered once daily in a capsule-based inhalation device

** INSM says it plans to initiate a late-stage trial for the drug in early 2026

** Up to last close, stock up 2.4% YTD

(Reporting by Christy Santhosh, Padmanabhan Ananthan and Kamal Choudhury)

((Christy.Santhosh@thomsonreuters.com))